Advertisement

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

      Abstract

      Purpose

      To estimate how much the improvement in bone mass accounts for the reduction in risk of vertebral fracture that has been observed in randomized trials of antiresorptive treatments for osteoporosis.

      Methods

      After a systematic search, we conducted a meta-analysis of 12 trials to describe the relation between improvement in spine bone mineral density and reduction in risk of vertebral fracture in postmenopausal women. We also used logistic models to estimate the proportion of the reduction in risk of vertebral fracture observed with alendronate in the Fracture Intervention Trial that was due to improvement in bone mineral density.

      Results

      Across the 12 trials, a 1% improvement in spine bone mineral density was associated with a 0.03 decrease (95% confidence interval [CI]: 0.02 to 0.05) in the relative risk (RR) of vertebral fracture. The reductions in risk were greater than predicted from improvement in bone mineral density; for example, the model estimated that treatments predicted to reduce fracture risk by 20% (RR = 0.80), based on improvement in bone mineral density, actually reduce the risk of fracture by about 45% (RR = 0.55). In the Fracture Intervention Trial, improvement in spine bone mineral density explained 16% (95% CI: 11% to 27%) of the reduction in the risk of vertebral fracture with alendronate.

      Conclusion

      Improvement in spine bone mineral density during treatment with antiresorptive drugs accounts for a predictable but small part of the observed reduction in the risk of vertebral fracture.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cheng X.G.
        • Lowet G.
        • Boonen S.
        • et al.
        Prediction of vertebral and femoral strength in vitro by bone mineral density measured at different skeletal sites.
        J Bone Miner Res. 1998; 13: 1439-1443
        • Marshall D.
        • Johnell O.
        • Wedel H.
        Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
        BMJ. 1996; 312: 1254-1259
        • Black D.M.
        • Cummings S.R.
        • Karpf D.B.
        • et al.
        Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
        Lancet. 1996; 348: 1535-1541
        • Cummings S.R.
        • Black D.M.
        • Thompson D.E.
        • et al.
        Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures.
        JAMA. 1998; 280: 2077-2782
        • Liberman U.A.
        • Weiss S.R.
        • Bröll J.
        • et al.
        Effect of three years’ treatment with oral alendronate on bone mineral density and fracture incidence in women with postmenopausal osteoporosis.
        N Engl J Med. 1995; 333: 1437-1443
        • Watts N.B.
        • Harris S.T.
        • Genant H.K.
        • et al.
        Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
        N Engl J Med. 1990; 323: 73-79
        • Storm T.
        • Thamsborg G.
        • Steiniche T.
        • et al.
        Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
        N Engl J Med. 1990; 322: 1265-1671
        • Lufkin E.G.
        • Wahner H.W.
        • O’Fallon W.M.
        • et al.
        Treatment of postmenopausal osteoporosis with transdermal estrogen.
        Ann Intern Med. 1992; 117: 1-9
        • Overgaard K.
        • Hansen M.A.
        • Jensen S.B.
        • Christiansen C.
        Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
        BMJ. 1992; 305: 556-561
        • Ettinger B.
        • Black D.M.
        • Mitlak B.E.
        • et al.
        Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene.
        JAMA. 1999; 282: 637-645
        • Cummings S.R.
        • Black D.M.
        • Vogt T.M.
        Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs.
        J Bone Miner Res. 1996; 11: S102
        • Wilkin T.J.
        Changing perceptions in osteoporosis.
        BMJ. 1999; 318: 862-865
        • Wasnich R.D.
        • Miller P.D.
        Antifracture efficacy of antiresorptive agents are related to changes in bone density.
        J Clin Endocrinol Metab. 2000; 85: 231-236
        • Chestnut C.H.
        • Silverman S.
        • Andriano K.
        • et al.
        A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis.
        Am J Med. 2000; 109: 267-331
        • Harris S.T.
        • Watts N.B.
        • Jackson R.D.
        • et al.
        Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis.
        Am J Med. 1993; 95: 557-567
        • Genant H.K.
        • Chestnut C.H.
        • Eisman J.A.
        • et al.
        Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis.
        Bone. 1998; 23: S175
        • Harris S.T.
        • Watts N.B.
        • Genant H.K.
        • et al.
        Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.
        JAMA. 1999; 282: 1344-1352
        • Reginster J.-Y.
        • Minne H.W.
        • Sorensen O.H.
        • et al.
        Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.
        Osteoporos Int. 2000; 11: 83-91
        • Petiti D.
        Meta-analysis, Decision Analysis and Cost Effectiveness Analysis.
        in: New York University Press, New York, New York1994: 60-62
        • Black D.M.
        • Nevitt M.C.
        • Palermo L.
        • et al.
        Prediction of new vertebral deformities.
        J Bone Miner Res. 1993; 8: S135
        • Freedman L.S.
        • Graubard B.I.
        • Schatzkin A.
        Statistical validation of intermediate endpoints for chronic diseases.
        Stat Med. 1992; 11: 167-168
        • Fieller E.C.
        The biological standardization of insulin.
        J R Stat Soc. 1940; 7: 1-15
        • Parfitt A.M.
        Trabecular bone architecture in the pathogenesis and prevention of fracture.
        Am J Med. 1987; 82: 68-72
        • Recker R.R.
        Architecture and vertebral fracture.
        Calcif Tissue Int. 1993; 53: S139-S142
        • Moskilde L.
        Vertebral structure and strength in vivo and in vitro.
        Calcif Tissue Int. 1993; 53: S121-S125
        • Garnero P.
        • Hausherr E.
        • Chapuy M.C.
        • et al.
        Markers of bone resorption predict hip fracture in elderly women.
        J Bone Miner Res. 1996; 10: 1531-1538
        • Roe E.B.
        • Sanchez S.D.
        • del Puerto G.A.
        • et al.
        Parathyroid hormone 1-34 (hPTH) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis—results from a placebo-controlled randomized trial.
        J Bone Miner Res. 1999; 14: S137
        • Cann C.E.
        • Roe E.B.
        • Sanchez S.D.
        • Arnaud C.D.
        PTH effects in the femur.
        J Bone Miner Res. 1999; 14: S137
        • Peel N.F.A.
        • Eastell R.
        Comparison of rates of bone loss from the spine measured using two manufacturers’ densitometers.
        J Bone Miner Res. 1995; 10: 1796-1801
        • Carter D.R.
        • Hayes W.C.
        Bone compressive strength: the influence of density and strain rate.
        Science. 1976; 194: 1164-1176
        • Keaveny T.M.
        • Hayes W.C.
        A 20-year perspective on the mechan-ical properties of trabecular bone.
        J Biomech Eng. 1993; 115: 534-542
        • Riggs B.L.
        • Melton L.J.
        • O’Fallon W.M.
        Drug therapy for vertebral fractures in osteoporosis.
        Bone. 1996; 18: 197S-201S
        • Cauley J.A.
        • Seeley D.G.
        • Ensrud K.
        • et al.
        Estrogen replacement therapy and fractures in older women.
        Ann Intern Med. 1995; 122: 9-16
        • Faulkner K.G.
        Bone matters.
        J Bone Miner Res. 2000; 15: 183-187
        • Black D.M.
        • Palermo L.
        • Nevitt M.C.
        • et al.
        • Study of Osteoporotic Fractures Research Group
        Defining incident vertebral deformity.
        J Bone Miner Res. 1999; 14: 90-101
        • Buyse M.
        • Molenberghs G.
        • Burzykowski T.
        • et al.
        Statistical validation of surrogate endpoints.
        Drug Inf J. 2000; 34 (447–445)